Vanguard Group
NEUP

Vanguard Group’s Neuphoria Therapeutics NEUP Stock Holding History

Vanguard Group’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$81.3K Hold
20,950
– – ﹤0.01% 4196
2025
Q3 		$247K Buy
+20,950
New +$195K ﹤0.01% 4091

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Vanguard Group's NEUP Position: Q4 2025 in Review

Vanguard Group held its Neuphoria Therapeutics (NEUP) position steady in Q4 2025 at 20,950 shares worth $81.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4196.

Vanguard Group first reported a position in NEUP in Q3 2025 and has held it in 2 quarters since. The position peaked at $247K in Q3 2025. 21 funds tracked by Wall St. Rank hold NEUP as of Q4 2025.

  • Vanguard Group held 20,950 shares of Neuphoria Therapeutics worth $81.3K as of Q4 2025.
  • Vanguard Group left its Neuphoria Therapeutics share count unchanged in Q4 2025.
  • Neuphoria Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4196 holding.
  • Vanguard Group first reported a position in Neuphoria Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Vanguard Group's Neuphoria Therapeutics position peaked at $247K in Q3 2025.
  • 21 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.